On Friday, Shares of Prima Biomed Ltd. (NASDAQ:PBMD), lost -6.16% to $1.60.
Prima Biomed Ltd, declared that it has received EUR 226,055 (about A$320,000) in a cash rebate from the French state under the Crédit d’Impôt Recherche scheme. The cash rebate was paid in respect of expenditure incurred by Prima’s wholly owned partner, Immutep on French R&D activities in the 2014 calendar year, related to the Company’s LAG-3 programs.
The “Crédit d’Impôt Recherche” (CIR), meaning “Research Tax Credit”, is a French government tax incentive first introduced in 1983 by which French companies doing research and development activity in Europe can be reimbursed 30% of eligible expenditure. Unlike most direct aid to R&D and innovation in industrial countries, the CIR system does not target any specific sector or type of company. Expenditure eligible for CIR comprises salaries for researchers, operational expenses, depreciation of assets used in research projects, intellectual protection expenses and technology watch expenses.
Prima BioMed Ltd. researches, develops, and commercializes medical biotechnology products in Australia. The company develops immunocellular therapeutic products for the treatment of cancer. Its lead product is CVac, an autologous dendritic cell-based product presently in clinical trials for ovarian and pancreatic cancer patients. Prima BioMed Ltd. is based in Sydney, Australia.
Shares of TrueCar Inc (NASDAQ:TRUE), declined -0.71% to $12.51, during its last trading session.
TrueCar, the negotiation-free car buying and selling mobile marketplace, projects retail auto sales to consumers will rise 7.9 percent in June from a year ago as robust demand, married with promotions by automakers, kicks off the summer-selling season. Total industry volume, counting fleet deliveries, may enhance by 6.3 percent.
New vehicle sales, counting those to daily rental and commercial fleets, should rise to 1,510,000 units this month from 1,420,994 a year ago, the highest since 2005. Deliveries may enhance 2 percent on a daily selling rate (DSR) basis, adjusting for one more selling day contrast to June 2014. Moreover, the seasonally adjusted annualized rate (SAAR) for total light vehicle sales should reach 17.4 million units in June, up 2.7 percent from last year’s 16.9 million-unit SAAR.
TrueCar, Inc. operates as an Internet-based information, technology, and communication services company. The company operates its platform on the TrueCar Website and TrueCar mobile applications. It also customizes and operates its platform for its affinity group marketing partners, counting financial institutions, membership-based organizations, and employee buying programs for large enterprises.
At the end of Friday’s trade, Shares of Biogen Inc (NASDAQ:BIIB), lost -0.62% to $408.73.
Biogen Inc, declared that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) of ALPROLIX (rFIXFc), a recombinant factor IX Fc fusion protein product candidate for the treatment of hemophilia B. This validation signifies the initiation of the EMA’s review process.
The MAA comprises results from two global, Phase 3 clinical trials examining the efficacy, safety and pharmacokinetics (a measure of the presence of the therapy in a person’s body over time) of ALPROLIX for hemophilia B: the pivotal B-LONG study for formerly treated adults and adolescents, and Kids B-LONG study for formerly treated children under age 12.
Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally.
Finally, Incyte Corporation (NASDAQ:INCY), ended its last trade with -0.38% loss, and close at $ 104.05.
Incyte Corporation, declared that it has created two new units to better position the organization for future growth in the U.S. and internationally. One of these is a U.S. country organization that will lead commercial and medical affairs in the United States. In the future, the company anticipates to establish other similar country- or regionally-based organizations. The other new unit is a Global Product Strategy and Business Development & Licensing (BD&L) unit that will lead global competitive strategies for Incyte’s expanding portfolio beyond Jakafi (ruxolitinib), in addition to review business development opportunities.
Jim Daly has indicated he will leave Incyte later this month, and commented, “My decision to return to California was a personal one. I leave Incyte knowing that the business is performing well and that the team is well-prepared to grow Jakafi, and to advance Incyte’s pipeline of innovative medicines, as the company seeks to make a major difference for cancer patients in the years ahead.”
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. It offers JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), counting primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line comprises ruxolitinib, which is in Phase III clinical trial for pancreatic cancer; and in Phase II trial for the treatment of breast cancer, non-small cell lung cancer, and colorectal cancer, in addition to INCB39110 that is in Phase I/II trial for malignancies; and in Phase II trial for non-small cell lung cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
